Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Crescita Therapeutics Inc T.CTX

Alternate Symbol(s):  CRRTF

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company’s prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products ...


TSX:CTX - Post by User

User Avatar Image
(1716)
•••
  • Possibleidiot01X
Post by Possibleidiot01on Aug 06, 2025 9:09am
104 Views
Post# 36669278

Q2

Q2I appreciate managment making this one point clear.

“We are pleased with the positive results for the quarter, which showed significant year-over-year improvement and strengthened our position as we enter the second half of 2025. Q2 was marked by the successful fulfillment of key purchase orders with a new manufacturing customer, and the continued growth in our Skincare segment,” commented Serge Verreault, President and Chief Executive Officer of Crescita. “While non-recurring in nature, the mutual termination agreement with Croma added approximately $900,000 to our topline and cash balance. When excluding its impact on our results, we achieved a breakeven Adjusted EBITA for the quarter,” added Mr. Verreault.

<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities